Free  DSM: still riddled with conflicts of interest

Marketing Authorisations

Finerenone (Kerendia°) in chronic kidney disease with albuminuria associated with type 2 diabetes

Lipegfilgrastim (Lonquex°) in the prevention of chemotherapy-induced neutropenia from 2 years of age

Durvalumab (Imfinzi°) in the first-line treatment of certain biliary tract cancers

Durvalumab (Imfinzi°) + tremelimumab (Imjudo°) as first-line treatment for certain advanced hepatocellular carcinomas

Durvalumab (Imfinzi°) + tremelimumab (Imjudo°) + a platinum compound as first-line treatment for certain metastatic lung cancers

Fenfluramine (Fintepla°) in Lennox-Gastaut syndrome

Solifenacin + tamsulosin (Vecalmys°) in benign prostatic hyperplasia

Editors' opinion. Absurd!

Nivolumab (Opdivo°) as neoadjuvant treatment in certain lung cancers at high risk of recurrence

Queries and comments. Which beta blocker should be used to prevent rupture of oesophageal varices?

Adverse Effects

Carbamazepine and pregnancy: malformations and neurodevelopmental disorders (continued)

Short-term interruption of treatment with a xaban or dabigatran: sometimes fatal thrombosis

Antidepressants and COPD: pneumonia and exacerbations?

Amiodarone + xaban: bleeding

Pralsetinib: extrapulmonary tuberculosis

Triptans: stroke and myocardial infarction

Diclofenac and other NSAIDs: allergic angina (Kounis syndrome)

Common stem: -(fl)oxacin

Outlook

Environmental impact of drugs: taking drug utilisation data into account

Clinical evaluation: too many endpoint changes during trials

Free  European "pharmaceutical package": letter on clinical data exclusivity

Masthead

Free  Masthead